Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is listed today as Keros Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $56 M | No. 3 | $50 to $250 million | equity | SEC | |
| Nov 2018 | $12 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2016 | $11 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Keros Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License revenue $205.36 million (84%), License revenue $205.36 million (84%), Service and other revenue $38.71 million (16%).
Annual report (SEC XBRL) · Dec 2025
Keros Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2020
Products and services#
No products or services of Keros Therapeutics, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arkin Bio Venture Partners Ltd. | Venture capital | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Arkin Bio Ventures Limited Partnership | Venture capital | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Jasbir Seehra | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series C preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Pontifax (Cayman) IV L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pontifax (China) IV L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pontifax (Israel) IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pontifax Late Stage Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pontifax Late Stage GP Ltd. | Company | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pontifax Management 4 G.P. (2015) Ltd. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 20 investors.
Largest shareholders today
Institutions holding Keros Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$40 M17.84%
- Nantahala Capital Management, LLC$17 M7.59%
- Vanguard Capital Management LLC$9 M4.24%
- AQR Capital Management LLC$9 M4.10%
- Orbimed Advisors LLC$9 M3.87%
- Mackenzie Financial Corp$8 M3.79%
- Federated Hermes, Inc.$8 M3.60%
- Vanguard Portfolio Management LLC$7 M3.25%
- Madison Avenue Partners, LP$7 M3.19%
- Two Sigma Investments, LP$6 M2.79%
- State Street Corp$6 M2.76%
- Geode Capital Management, LLC$6 M2.53%
- Jacobs Levy Equity Management, Inc$5 M2.35%
- Qube Research & Technologies Ltd$5 M2.22%
- Dimensional Fund Advisors LP$5 M2.06%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Claudia Ordonez | Executive officer | Mar 2020 |
| Jasbir Seehra | Executive officer | Mar 2020 |
| Jenn Lachey | Executive officer | Mar 2020 |
| Keith Regnante | Executive officer | Mar 2020 |
| Jasbir S. Seehra | Executive officer | Nov 2018 |
| Alon Lazarus | Director | Mar 2020 |
| Carl Gordon | Director | Mar 2020 |
| Jasbir Seehra | Director | Mar 2020 |
| Julius Knowles | Director | Mar 2020 |
| Nima Farzan | Director | Mar 2020 |
| Ran Nussbaum | Director | Mar 2020 |
| Zafrira Avnur | Director | Mar 2020 |
| Alon S. Lazarus | Director | Nov 2018 |
| Jasbir S. Seehra | Director | Nov 2018 |
| Julius S. Knowles | Director | Nov 2018 |
| Ohad S. Hammer | Director | Nov 2018 |
| Ran S. Nussbaum | Director | Nov 2018 |
| Zafrira S. Avnur | Director | Nov 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.